These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16431008)

  • 1. Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: the role of clinical, psychosocial and genetic variables.
    Dotoli D; Spagnolo C; Bongiorno F; Zanardi R; Serretti A; Smeraldi E; Franchini L
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):442-8. PubMed ID: 16431008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study.
    Terra JL; Montgomery SA
    Int Clin Psychopharmacol; 1998 Mar; 13(2):55-62. PubMed ID: 9669185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of response to fluvoxamine in nondemented elderly compared to younger patients affected by major depression.
    Zanardi R; Cusin C; Rossini D; De Ronchi D; Serretti A
    J Clin Psychopharmacol; 2003 Dec; 23(6):535-9. PubMed ID: 14624182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder.
    Volkers AC; Tulen JH; van den Broek WW; Bruyn JA; Passchier J; Pepplinkhuizen L
    Pharmacopsychiatry; 2004 Jan; 37(1):18-25. PubMed ID: 14750044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population.
    Kishi T; Kitajima T; Ikeda M; Yamanouchi Y; Kinoshita Y; Kawashima K; Okochi T; Ozaki N; Iwata N
    Neuropsychobiology; 2009; 59(4):234-8. PubMed ID: 19571598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients.
    Naito S; Sato K; Yoshida K; Higuchi H; Takahashi H; Kamata M; Ito K; Ohkubo T; Shimizu T
    Psychiatry Clin Neurosci; 2007 Aug; 61(4):421-7. PubMed ID: 17610668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study.
    Anghelescu IG; Kohnen R; Szegedi A; Klement S; Kieser M
    Pharmacopsychiatry; 2006 Nov; 39(6):213-9. PubMed ID: 17124643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
    Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
    Psychiatry Clin Neurosci; 2008 Jun; 62(3):301-6. PubMed ID: 18588590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.
    Kasper S; Volz HP; Möller HJ; Dienel A; Kieser M
    Eur Neuropsychopharmacol; 2008 Nov; 18(11):803-13. PubMed ID: 18694635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
    Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
    J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees.
    Franchini L; Serretti A; Gasperini M; Smeraldi E
    J Psychiatr Res; 1998; 32(5):255-9. PubMed ID: 9789202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brief dynamic therapy combined with pharmacotherapy in the treatment of major depressive disorder: long-term results.
    Maina G; Rosso G; Bogetto F
    J Affect Disord; 2009 Apr; 114(1-3):200-7. PubMed ID: 18728001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
    Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
    J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder.
    Okuda A; Suzuki T; Kishi T; Yamanouchi Y; Umeda K; Haitoh H; Hashimoto S; Ozaki N; Iwata N
    Psychiatry Clin Neurosci; 2010 Jun; 64(3):268-73. PubMed ID: 20602727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission and relapse after the first hospital admission in psychotic depression: a 4-year naturalistic follow-up.
    Naz B; Craig TJ; Bromet EJ; Finch SJ; Fochtmann LJ; Carlson GA
    Psychol Med; 2007 Aug; 37(8):1173-81. PubMed ID: 17335639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery from a recurrent major depressive episode.
    Kravitz HM; Bloom RW; Fawcett J
    Depress Anxiety; 2000; 12(1):40-3. PubMed ID: 10999244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-generation antidepressant discontinuation and depressive relapse in adult patients with bipolar depression: results of a retrospective database analysis.
    Fu AZ; Christensen DB; Hansen RA; Liu GG
    Clin Ther; 2006 Jun; 28(6):979-89. PubMed ID: 16860180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.